Linde Kehmann Sign in to save

OpenAlex profile details not fetched

–

Citations

–

h-index

–

i10-index

Patent citations

–

Works (all)

Aachen papers

Departments & institutes in Aachen

No department could be parsed from this author's affiliation strings.

Affiliations exactly as printed on papers (8)

2× Servier Deutschland GmbH, München, Germany
1× Department of Hepatology and Gastroenterology, Charité University Medicine Berlin, Campus Virchow Klinikum, 13353, Berlin, Germany
1× Servier Deutschland GmbH, 80687, München, Germany
1× Servier Germany, Munich, Germany
1× Charité University Medicine Berlin, Berlin, Germany;
1× Charité University Medicine Berlin, Berlin, Germany
1× Department of Hepatology and Gastroenterology, Campus Virchow Klinikum, Charité University Medicine Berlin, 13353, Berlin, Germany
1× Servier Deutschland GmbH, Elsenheimerstr, 53, 80687, München, Germany

Papers 7 stored

All · Aachen affiliation only

Study protocol: a phase II study of trifluridine/tipiracil plus liposomal irinotecan as second-line therapy in advanced biliary tract cancer (TRITICC 2)
2026 BMC Cancer article Medicine Cholangiocarcinoma and Gallbladder Cancer Studies Open access

0

citations
321P Results of an open-label, single-arm phase II trial investigating the efficacy and safety of trifluridine/tipiracil combined with irinotecan as a second-line therapy in patients with cholangiocarcinoma (TRITICC)
2025 Annals of Oncology article Medicine Cholangiocarcinoma and Gallbladder Cancer Studies Open access

1

citations
First results of an open-label, single arm phase II trial investigating the efficacy and safety of trifluridine/tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma.
2025 Journal of Clinical Oncology conference-abstract Medicine Cholangiocarcinoma and Gallbladder Cancer Studies

2

citations
First safety analysis of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with oxaliplatin and 5-fluoruracil/folinic acid followed by curative surgical resection in patients with hepatic oligometastatic adenocarcinoma of the pancreas (HOLIPANC).
2025 Journal of Clinical Oncology conference-abstract Medicine Pancreatic and Hepatic Oncology Research Open access

0

citations
Open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with oxaliplatin and 5-fluorouracil/folinic acid followed by curative surgical resection in patients with hepatic oligometastatic adenocarcinoma of the pancreas (HOLIPANC).
2023 Journal of Clinical Oncology conference-abstract Medicine Pancreatic and Hepatic Oncology Research cited by 1 patent

0

citations
Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC)
2023 BMC Cancer article Medicine Cholangiocarcinoma and Gallbladder Cancer Studies Open access

5

citations
Study protocol of an open-label, single-arm, phase II trial investigating the efficacy and safety of trifluridine/tipiracil combined with irinotecan as a second-line therapy in patients with cholangiocarcinoma (TRITICC).
2022 Journal of Clinical Oncology conference-abstract Medicine Cholangiocarcinoma and Gallbladder Cancer Studies Open access

1

citations

7 results

Linde Kehmann ▲ Sign in to save

Departments & institutes in Aachen

Papers 7 stored

Linde Kehmann Sign in to save